ASTRAZENECA PLC
AZN | London Stock ExchangeBusiness Summary
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
Country of Incorporation
United Kingdom
Incorporation Date
1992-06-17
Business Sector
Pharmaceuticals & Medical Research
Company Address
1 Francis Crick Avenue, Cambridge Biomedical Campus
Get access to the below data and more business development tools by signing up for the MENA Company Data product.
- Ownership details
- Corporate structure
- Business classification
- Officers & Directors contact details
- Full company contact details
Multiply your reach by contributing your content to LSEG
LSEG contributed content reaches tens of thousands of buy and sell side professionals around the world through an integrated suite of market intelligence and transaction platforms.NEWS ON THIS COMPANY
TOP PICKS
MOST READ
MOST WATCHED
MOST POPULAR
1.
2.
3.
4.
5.
